Scutellarin Alleviates Pulmonary Hypertension by Inhibiting the NF-κB/NLRP3 Signaling Pathway to Suppress Inflammation and Pyroptosis.
文献摘要
Background : Pulmonary arterial hypertension (PAH) is a progressive fatal cardiovascular disorder characterized by pulmonary vascular remodeling, elevated pulmonary vascular resistance and right heart failure, mainly driven by chronic inflammation and aberrant cell death. Scutellarin (SCU), a natural flavonoid with anti-inflammatory and vasculoprotective properties, exhibits unknown therapeutic effects and mechanisms against PAH. This study aimed to explore the therapeutic potential of SCU for PAH and to clarify its underlying mechanism targeting NF-κB/NLRP3 signaling-mediated inflammation and pyroptosis. Methods : Network pharmacology and molecular docking were performed to screen the core therapeutic targets and binding activity of SCU against PAH. A Su5416/hypoxia (SuHx)-induced rat PAH model was established for in vivo verification, and hypoxia-stimulated human pulmonary artery smooth muscle cells (HPASMCs) were used for in vitro functional validation. Results : A total of 100 overlapping targets of SCU and PAH were identified, with core hub targets enriched in inflammation and pyroptosis pathways, and stable binding between SCU and core targets was verified. SCU significantly improved right ventricular function and pulmonary hemodynamics, alleviating pulmonary vascular remodeling and perivascular fibrosis in PAH rats. Mechanically, SCU blocked NF-κB/NLRP3 signaling, inhibited cell pyroptosis and inflammatory cytokine release, and downregulated vascular remodeling-related protein expression. Additionally, SCU dose-dependently suppressed the hypoxia-induced proliferation and pyroptosis of HPASMCs. Conclusions : SCU ameliorates PAH-induced pulmonary vascular remodeling and right ventricular dysfunction via inhibiting the NF-κB/NLRP3 inflammatory and pyroptosis signaling cascade, which supports its potential as a promising natural candidate agent for PAH treatment.